Daveen Chopra

“Yeah, as you said, exactly, you know, right now we're expecting both the data to be released at TCT this year. I think we'll all look at the data together, and our expectation is for a Q4 approval in the U.S. is our current planning right now.”

“I think overall in TMTT, obviously, we continue to be excited about TMTT. We're seeing that this comprehensive portfolio of repair and replacement is really enabling personalized therapy, which helps get the best clinical results for patients.”

“And if you look at existing technologies out there, we think there's still unmet patient needs. And that's where we believe, obviously, that we can come out with a technology in this new therapeutic area for Edward Surgical.”

“For EVOQUE, there is a lot of excitement from both physicians and patients regarding how the technology is transforming their lives. In the TRISCEND II study, we have baseline clinical data for this product, and our real-world results are showing outcomes that are equal to or even better than those in TRISCEND II.”

“We can't be more excited about Evoque as a new category for us. Right? It's a great product. And the NCD, as you know, was effective now in March of 2025, and this is a transcatheter tricuspid valve replacement NCD.”